Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 11 of 38
GSK financials should look good but clinic is the focus
Clinical results have been more mixed with Myeloma treatment Blenrep dropped after disappointing trial results
GSK growing optimistic on HIV but long term challenges remain - analyst
GSK shows increasing confidence in new HIV treatments but longer term challenges remain, according to Jefferies
GSK gets chunky Citi target upgrade after Zantac ruling
Legal precedent also suggests that ongoing state-based litigation is unlikely to result in a material settlement
Hardware & electrical equipment
FIVE at FIVE: GSK soars on court ruling; Pint price hikes; FTSE 100 slides; Microsoft's Nintendo deal; Apple welcomes Taiwan chip investment
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
GSK halts US marketing process for Blenrep after recent disappointing trial data
The news followed the previously announced outcome of the DREAMM-3 phase III trial which failed to meet the FDA requirements, wiping around £1.7bn of the FTSE 100-listed drugs group’s share price
GSK slapped with 'sell' rating over long-term risks
On the plus side for the drug group, analysts said it has time and options, including potentially allocating more cash to "smooth over" the potential 2027 bottleneck
GSK says second-line applications of new cancer drug will be restricted
The front-line use of Zejula, which has been developed to treat epithelial ovarian, fallopian tube, or primary peritoneal cancers, remains unchanged
GSK slide wipes off £2.5bn, but for one broker this puts the stock in bargain basement territory
The tumble follows a clinical trial failure for a cancer treatment it developed
GSK loses almost £1.7bn value after drug trial failure
Blenrep was deemed no better than the current standard of care in helping people with late-stage, hard-to-treat multiple myeloma, a type of bone marrow cancer
GSK's new antibiotic a handy add-on, suggests Deutsche Bank
Fluoroquinolones treat a quarter of the 10mln+ annual US UTI cases
GSK to submit urinary infection treatment for approval after trial success
GSK has halted the trials early after an independent assessment concluded it has already met its primary endpoint
GSK results top City forecasts, UBS sees consensus EPS forecasts rising 3%
The broker highlighted strong growth in Vaccines where sales of shingles product, Shingrix, came in 11% ahead of forecast.